Here are the most anticipated abstracts to keep an eye on going into the 2025 ASCO Gastrointestinal Cancers Symposium.

The biologics license application for RP1 (vusolimogene oderparepvec) plus nivolumab in advanced melanoma was accepted by the ...

Molecular oncology is revolutionizing cancer care by using genetic profiling to tailor personalized treatments, improving ...

In an interview, Paolo Ghia, MD, PhD, discussed updated data from the phase 2 CAPTIVATE trial of ibrutinib and venetoclax in ...

During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed treatment for a patient with chronic ...

The phase 3 AURIGA study evaluated daratumumab (Darzalex) and lenalidomide vs lenalidomide maintenance in patients with newly diagnosed multiple myeloma who were in very good partial response, minimal ...

OST-HER2 led to significant 12-month event-free survival and demonstrated favorable overall survival trends at 1 and 2 years ...

In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with ...

During a Community Case Forum event in partnership with the Medical Oncology Association of Southern California, Edward S.

A panelist discusses how, despite recent advances in relapsed/refractory follicular lymphoma treatment, important unmet needs ...

A study by UVA Health found that while ChatGPT Plus holds potential for enhancing diagnoses, physicians need better training ...

HNSCC, whereas the combination of durvalumab and cetuximab showed limited success. Abenacianine received fast track designation for lung cancer surgery, the combination of amivantamab and Lazertinib ...